Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Qurate Retail Inc Series A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Qurate Retail Inc Series A trades at $0.08 (market cap $1.12M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4008.9× Qurate Retail Inc Series A's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ACAD | QVCAQ | |
|---|---|---|
Market Cap | $4.49B | $1.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $15.03 |
52-Week Low | $20.06 | $0.07 |
Enterprise Value | $3.69B | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
QVCAQ trades at $0.109, up 37.97% in 24 hours, but technical signals are bearish with 13 sell signals on moving averages. The company reported a net loss of $2.44 billion in 2025, with negative shareholder equity of $971 million and a debt-to-asset ratio of 77.57%. Recent news highlights QVC's 40th anniversary and TikTok Shop partnership (PRNewsWire, 2026-05-28).
The outlook remains highly speculative due to persistent losses, negative equity, and high leverage. Risks include financial distress and competitive pressures, while any positive sentiment hinges on operational turnarounds. Investors should approach with caution given the fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
